Celebrating 60 years of melanoma research to save lives
19 April 2017
Melanoma Institute Australia is proud to be celebrating an important milestone – the 60th anniversary of melanoma research and Australian-led global efforts to find a cure.
It was back in 1957 when Sydney Hospital recorded its first data on a melanoma patient. This patient record marked the beginning of what was to become the Melanoma Research Database (MRD), which is now the biggest database of its kind in the world. With more than 41,000 patient records, the MRD continues to play a vital role in underpinning the ground-breaking work of Melanoma Institute Australia (MIA) and around the world.
“Melanoma used to be viewed as a disease with a dismal outlook for patients, but I am pleased to say that today things are much different,” said Professor Richard Scolyer, MIA’s Conjoint Medical Director. “The foresight of our colleagues at Sydney Hospital to start recording patient data back in 1957 set us on a path towards greater understanding of the disease, and we are now leading the world in advancing melanoma treatment and research.”
“Life expectancy for advanced melanoma patients has tripled in the last five years, and we are even seeing some patients who are recovering fully,” comments Professor Georgina Long, MIA’s Conjoint Medical Director. “However we still have a long way to go, with one Australian dying from melanoma every six hours.”
Critical to our story is the work of Professor Gerry Milton (pictured) of the Sydney Melanoma Unit (now Melanoma Institute Australia) who in 1968 was trying to better understand the disease. He recruited Dr Helen Shaw to collect and collate all the records of melanoma patients treated at Sydney Hospital over the previous decade. Always forward thinking, the Unit decided to embrace the “high technology” of the day and convert the entire patient catalogue to punch cards – and so the database was born. The detailed patient records included diagnosis, treatment and disease course over time.
The MRD database is now managed by a team including IT specialists and clinical data managers, dedicated to its refinement, preservation and cultivation. It serves as an invaluable resource to identify and extract specific sub-sets of information for research projects related to causes, diagnosis, prognosis and treatment outcomes in melanoma patients. The knowledge gained from these studies assists in the management of melanoma patients around the world.
“We celebrate this Diamond Anniversary with much gratitude to our professional predecessors for their pioneering work that was way ahead of its time. We also have immense appreciation for those thousands of melanoma patients who over the last 60 years have allowed their clinical records to be included in our research database which have enabled us to improve the lives of melanoma patients that have followed them,” Professor Scolyer said.
“They have quite literally given the gift of life to other melanoma patients, and will be the unsung heroes when we finally achieve our goal of ending melanoma.”
In a recent issue of Cancer Cell journal, Prof Georgina Long AO and Prof Richard Scolyer discuss the challenge of bringing together clinical work and scientific research to underpin successful cancer research.
Clinicians around the world now have access to a new online calculator that predicts the risk that a patient’s primary melanoma has spread to nearby lymph nodes.
Professor Long has been appointed as an Officer (AO) of the Order of Australia (General Division) for distinguished service to medicine, particularly, to melanoma clinical and translational research, and to professional medical societies.
“I had a complete response within about six months. All of my tumours disappeared."
‘We are extremely proud of our ongoing contribution to the global effort to save lives from melanoma, with Dr Silva’s prestigious award proof that we continue to lead the way,'
MIA's Co-Medical Director, Professor Richard Scolyer, has achieved a Google Scholar h-index of 100.
We know what Melanoma March means to our community, so when we had to cancel our physical events, we created Melanoma March Virtual so that everyone across Australia could still connect to honour loved ones and support each other.
A must-read personal account by Garry Maddox in The Sydney Morning Herald of how immunotherapy is revolutionising melanoma treatment.
On Friday, a publication that lays out the steps needed to find out if a systematic screening program for melanoma would benefit all Australians was published in the Australia & New Zealand Journal of Public Health.
Melanoma March events have been cancelled. A Virtual March will be held on Sunday 29th March. Read this statement from MIA CEO Matthew Browne.
Thank you to the thousands of Aussies who bought ‘Game On Mole‘ t-shirts, took selfies, shared t-shirt pics on social media and started lifesaving conversations around sun safety and skin health.
Melanoma patients now have greater access to subsidised immunotherapy thanks to additional treatments today being listed on the PBS.
Brisbane couple Leon and Tamra Betts were, like thousands of others around Australia, on the couch watching MAFS when newlywed Natasha ran through her weekly beauty routine. When they heard the 26-year-old mention solarium use, they were shocked, and then saddened, prompting this open letter to all young Australians.
Professor Richard Scolyer, Co-Medical Director of Melanoma Institute Australia, will welcome international attendees this weekend to a sold-out, two-day course on ‘Pigmented Lesions and Other Hot Topics in Dermatopathology’.
It is time for a reality check on solariums.
They have no place in anyone’s beauty routine.
Throughout January our community created, hosted and participated in some amazing events, each of them helping us on our quest to reach zero deaths from melanoma.
Australian television presenter, interior designer and mother Kyly Clarke has been announced as the new Ambassador for Melanoma Institute Australia (MIA) and its national awareness and fundraising campaign Melanoma March.
Melanoma Institute Australia has recently partnered with three other organisations to boost support for melanoma patients and their carers across Australia.
Melanoma patients and their families across Western Australia will benefit from strengthened and expanded services with the merging of melanomaWA and Melanoma Institute Australia.
Australian researchers have played a critical role in the discovery of a potential new test to predict which early stage melanoma patients are at high risk of their disease recurring and progressing.